Clinical Trials
10 trialsNCT05983965 2026-04-17
Study of Tazemetostat in Lymphoid Malignancies
University of Alabama at Birmingham
Phase 1 Terminated
NCT04502446 2025-01-08
A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM)
CRISPR Therapeutics
Phase 1 Terminated
NCT02663518 2024-05-10
A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors
Pfizer
Phase 1 Terminated
NCT04219319 2022-08-16
LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T-cell Lymphoma
The First Affiliated Hospital with Nanjing Medical University
Phase 1 Terminated
NCT04973527 2022-08-16
LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T Lymphocyte Tumor
Beijing Boren Hospital
Phase 1 Terminated
NCT03834584 2020-08-25
A Study of AG-636 in the Treatment of Subjects With Advanced Lymphoma
Agios Pharmaceuticals, Inc.
Phase 1 Terminated
NCT00860171 2020-04-03
Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Fred Hutchinson Cancer Center
Phase 1 Terminated
NCT01742793 2020-03-04
RID
Yale University
Phase 1 Terminated
NCT00671112 2015-10-28
Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma
Case Comprehensive Cancer Center
Phase 1 Terminated
NCT00880867 2011-07-20
Intratumoral Poly-ICLC Plus Low Dose Local Radiation in Low Grade Recurrent B and T Cell Lymphoma
Nevada Cancer Institute
Phase 1 Terminated